|
| related topics |
| {control, financial, internal} |
| {product, candidate, development} |
| {customer, product, revenue} |
| {personnel, key, retain} |
| {loan, real, estate} |
| {property, intellectual, protect} |
| {stock, price, share} |
| {competitive, industry, competition} |
| {system, service, information} |
| {cost, operation, labor} |
|
|
The Company has a history of losses and may never achieve or maintain profitability.
The market for the Company s Common Stock is limited and its stock price is volatile.
There is uncertainty surrounding the Company s ability to successfully commercialize its biopreservative solutions.
The success of the Company s HypoThermosol and CryoStor biopreservative solutions is dependant, in part, on the commercial success of new cell and gene therapy technology.
The Company faces significant competition.
The Company s success will depend on its ability to attract and retain key personnel.
If the Company fails to protect its intellectual property rights, the Company s competitors may take advantage of its ideas and compete directly against it.
Because the life sciences industry is litigious, the Company may be sued for allegedly violating the intellectual property rights of others.
If the Company fails to obtain or maintain necessary regulatory clearances or approvals for products, or if approvals are delayed or withdrawn, the Company will be unable to commercially distribute and market its products or any product modifications.
The Company is dependent on outside suppliers for all of its manufacturing supplies.
The Company is transitioning to in-house manufacturing
Full 10-K form ▸
|
|
| related documents |
| 874015--3/16/2007--ISIS_PHARMACEUTICALS_INC |
| 899866--2/23/2009--ALEXION_PHARMACEUTICALS_INC |
| 806517--3/27/2009--PSYCHEMEDICS_CORP |
| 774517--6/25/2009--AMERICAN_CLAIMS_EVALUATION_INC |
| 1436083--7/20/2009--New_Millennium_Products |
| 22872--8/18/2006--COMPREHENSIVE_CARE_CORP |
| 1143848--3/28/2007--LSB_CORP |
| 1101026--4/14/2010--HEALTH_ENHANCEMENT_PRODUCTS_INC |
| 886530--3/16/2007--DATATRAK_INTERNATIONAL_INC |
| 58822--9/14/2010--LESCARDEN_INC |
| 1382574--4/15/2009--XCELLINK_INTERNATIONAL_INC. |
| 1078723--3/31/2010--INTERNATIONAL_FUEL_TECHNOLOGY_INC |
| 853695--3/31/2009--DRI_CORP |
| 1101026--5/18/2009--HEALTH_ENHANCEMENT_PRODUCTS_INC |
| 838879--4/15/2009--AMDL_INC |
| 728249--3/19/2010--INTERPHASE_CORP |
| 853695--4/15/2010--DRI_CORP |
| 1365022--7/7/2009--Coronado_Corp. |
| 1407161--3/31/2010--Titanium_Asset_Management_Corp |
| 1373444--12/1/2008--SOPAC_CELLULAR_SOLUTIONS_INC. |
| 1373444--11/29/2010--SOPAC_CELLULAR_SOLUTIONS_INC. |
| 1373444--12/15/2009--SOPAC_CELLULAR_SOLUTIONS_INC. |
| 1124105--3/11/2010--TARGACEPT_INC |
| 19871--3/23/2010--CHICAGO_RIVET_&_MACHINE_CO |
| 1077428--2/19/2010--TEXAS_CAPITAL_BANCSHARES_INC/TX |
| 731122--3/26/2010--CCFNB_BANCORP_INC |
| 1016504--9/28/2007--INTEGRATED_BIOPHARMA_INC |
| 752294--3/26/2010--ELECTRONIC_SYSTEMS_TECHNOLOGY_INC |
| 914475--2/7/2006--NEUROCRINE_BIOSCIENCES_INC |
| 704172--10/13/2010--PHI_GROUP_INC |
|